KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Emergent BioSolutions (EBS) Net Margin: 2010-2025

Historic Net Margin for Emergent BioSolutions (EBS) over the last 16 years, with Sep 2025 value amounting to 22.15%.

  • Emergent BioSolutions' Net Margin fell 1692.00% to 22.15% in Q3 2025 from the same period last year, while for Sep 2025 it was 9.62%, marking a year-over-year increase of 3230.00%. This contributed to the annual value of -18.26% for FY2024, which is 5421.00% up from last year.
  • Latest data reveals that Emergent BioSolutions reported Net Margin of 22.15% as of Q3 2025, which was up 360.14% from -8.52% recorded in Q2 2025.
  • Emergent BioSolutions' 5-year Net Margin high stood at 39.07% for Q3 2024, and its period low was -566.20% during Q2 2024.
  • Moreover, its 3-year median value for Net Margin was -16.08% (2024), whereas its average is -72.90%.
  • As far as peak fluctuations go, Emergent BioSolutions' Net Margin slumped by 48,884bps in 2024, and later surged by 55,768bps in 2025.
  • Over the past 5 years, Emergent BioSolutions' Net Margin (Quarterly) stood at 24.27% in 2021, then plummeted by 4,456bps to -20.29% in 2022, then spiked by 239bps to -17.90% in 2023, then skyrocketed by 182bps to -16.08% in 2024, then tumbled by 1,692bps to 22.15% in 2025.
  • Its last three reported values are 22.15% in Q3 2025, -8.52% for Q2 2025, and 30.60% during Q1 2025.